Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	2326521-71-3
Formula :	C₃₂H₃₅ClFN₇O₂
M.W :	604.12
SMILES Code :	N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C(CN(C4=C5C(Cl)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1
Synonyms :	MRTX849
MDL No. :	MFCD32263433
InChI Key :	PEMUGDMSUDYLHU-ZEQRLZLVSA-N
Pubchem ID :	138611145

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338

H358 cells	100-1000 nM	~9 months	To study the resistance of H358 cells to G12Ci (including adagrasib), results showed that resistant cells had significantly reduced sensitivity to the drug.	PMC8887821
H358 lung cancer cells	15.6 nM	1 hour	MRTX849 demonstrated covalent modification of KRASG12C in H358 lung cancer cells, indicating its inhibitory effect on KRASG12C.	PMC6954325
MIA PaCa-2 pancreatic cancer cells	15.6 nM	1 hour	MRTX849 demonstrated covalent modification of KRASG12C in MIA PaCa-2 pancreatic cancer cells, indicating its inhibitory effect on KRASG12C.	PMC6954325
NCI-H358	78 nmol/L	2 hours	To evaluate the potency of the inhibitors in reducing cellular active GTP-bound KRAS, the results showed that Adagrasib had an IC50 of 78 nmol/L	PMC11372373
MIAPACA2 cells	60 nM	72 hours	To study the effect of Adagrasib on KRASG12C mutant cells, results showed upregulation of ALDH1A1.	PMC11465744
H2122 cells	180 nM	72 hours	To study the effect of Adagrasib on KRASG12C mutant cells, results showed upregulation of ALDH1A1.	PMC11465744
NCI-H2122	150 nM	72 hours	To evaluate the antiproliferative effects of Adagrasib alone or in combination with BI-3406 on KRASG12C mutant cells, results showed that combination treatment had a stronger antiproliferative effect.	PMC11424490
SW837	150 nM	144 hours	To evaluate the antiproliferative effects of Adagrasib alone or in combination with BI-3406 on KRASG12C mutant cells, results showed that combination treatment had a stronger antiproliferative effect.	PMC11424490
NCI-H358	150 nM	72 hours	To evaluate the antiproliferative effects of Adagrasib alone or in combination with BI-3406 on KRASG12C mutant cells, results showed that combination treatment had a stronger antiproliferative effect.	PMC11424490
4NQO-L cells	0.03374 μM	96 hours	To investigate the sensitivity of 4NQO-L cells to MRTX849, results showed that MRTX849 significantly inhibited the MAPK pathway.	PMC11577641
4NQO-L-AcR1 cells	0.5225 μM	96 hours	To investigate the resistance of 4NQO-L-AcR1 cells to MRTX849, results showed that the expression of EGFR, HER2, and HER3 was upregulated in MRTX849-resistant cells.	PMC11577641
NCI-H2122	150 nM	72 hours	Evaluate the antiproliferative response of BI-3406 in combination with adagrasib	PMC11424490

mice	patient-derived xenograft (PDX) models of lung or colorectal cancer	oral	100 mg/kg	5 consecutive days, followed by a 2-day resting period as one cycle, for 3 cycles	To evaluate the anti-tumor effect of adagrasib in PDX models, results showed that adagrasib could inhibit tumor growth.	PMC8887821
mice	H358 xenograft model	oral	10 mg/kg	Five times per week for 3 weeks	MRTX849 demonstrated dose-dependent KRASG12C modification and KRAS pathway inhibition in the H358 xenograft model, showing significant anti-tumor efficacy.	PMC6954325
Mouse	KPC mouse model	Intraperitoneal injection	30 mg/kg	single dose	To evaluate the efficacy of MRTX1133 in the KPC mouse model, results showed that MRTX1133 significantly prolonged the overall survival of mice with PDAC and observed complete and durable tumor regressions.	PMC11528210
mice	NCI-H358 xenograft model	oral	5 mg/kg	Five times per week for 21 days	To assess the PK and PD properties of D3S-001 in NCI-H358 xenograft models, the results showed that D3S-001 dose-dependently inhibited the phosphorylation of ERK1/2 and RSK, suppressed the expression of all 10 MAPK signature genes, and reduced active GTP-bound RAS	PMC11372373
nude mice	MIAPACA2 xenograft model	oral gavage		Single administration	To evaluate the effect of Adagrasib on tumor growth in vivo, results showed that Adagrasib significantly inhibited tumor growth.	PMC11465744
Mice	Xenograft model	Oral	100 mg/kg	Daily for five days	To evaluate the tumor growth inhibitory effects of Adagrasib alone or in combination with BI-3406 on KRASG12C mutant tumors, results showed that combination treatment significantly enhanced tumor growth inhibition.	PMC11424490
C57BL/6 mice	4NQO-L tumor model	Oral	30 mg/kg	daily for 2 weeks	To evaluate the antitumor activity of the combination of MRTX849 and lapatinib, results showed that the combination treatment significantly delayed tumor growth and enhanced the infiltration of CD8+ T cells.	PMC11577641
mice	PDOX model	oral	30 mg/kg/day (MRTX849), 50 mg/kg/day (lapatinib)	Once daily for 25 days	To evaluate the therapeutic effect of RMC-4998 on sotorasib-resistant PDOX models, results showed that RMC-4998 significantly inhibited tumor growth.	PMC11364849

{[proInfo.proName]}

CAS No.: 2326521-71-3

{[proInfo.proName]}

CAS No.: 2326521-71-3

Product Citations

Alternative Products

Product Details of Adagrasib

Safety of Adagrasib

Related Pathways of Adagrasib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT05673187	NSCLC Stage IV\|KRAS P.G12C	PHASE2	RECRUITING	2026-03-01	Instiute Jules Bordet, Brussel... More >>s, Belgium\|Centre Hospitalier d'Avignon, Avignon, France\|Caen - CHU, Caen, France\|Le Mans - CHG, Le Mans, France\|H?pital de Marseille, Marseille, France\|Beaumont Hospital, Dublin, Ireland\|St James's Hospital, Dublin, Ireland\|University Hospital Limerick, Limerick, Ireland\|University Hospital Waterford, Waterford, Ireland\|Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy\|Santa Maria della Misericordia Hospital, Perugia, Italy\|Istituto Nazionale Tumori "Regina Elena", Rome, Italy\|AULSS2 Marca Trevigiana Treviso, Treviso, Italy\|Complejo Hospitalario Universitario a Coru?a, A Coru?a, Spain\|Alicante University Hospital, Alicante, Spain\|ICO Badalona - Hospital Germans Trias i Pujol, Badalona, Spain\|Hospital de Basurto, Bilbao, Spain\|ICO Bellvitge -H. Duran i Reynals / H. Bellvitge, L'Hospitalet De Llobregat, Spain\|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain\|Hospital Universitario Puerta de Hierro, Madrid, Spain\|Hospital General Universitario de Valencia (University Hospital Valencia), Valencia, Spain\|Christie NHS Manchester, Manchester, United Kingdom Less <<
NCT05634525	Metastatic Pancreatic Cancer	PHASE1	RECRUITING	2027-11-01	M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT06801418	Healthy Volunteers	PHASE1	NOT_YET_RECRUITING	2025-05-30	Local Institution - 0003, Lene... More >>xa, Kansas, 66219-9746, United States\|Local Institution - 0002, San Antonio, Texas, 78209-1028, United States\|Local Institution - 0001, Salt Lake City, Utah, 84124-1365, United States Less <<
NCT05853575	Advanced Cancer\|Metastatic Can... More >>cer\|Malignant Neoplasm of Lung Less <<	PHASE2	RECRUITING	2025-03-31	Providence Medical Foundation,... More >> Santa Rosa, California, 95403, United States\|Local Institution - 106, Chicago, Illinois, 60612, United States\|Local Institution - 103, Minneapolis, Minnesota, 55417, United States\|Local Institution - 105, Kansas City, Missouri, 64128, United States\|Veterans Affairs Medical Center (VAMC) - Durham, Durham, North Carolina, 27705, United States\|VA North Texas Healthcare System/Dallas VA Medical Center, Dallas, Texas, 75216-7167, United States\|Local Institution - 179, Cachoeiro Do Itapemirim, Espírito Santo, 29308-065, Brazil\|Local Institution - 178, Belo Horizonte, Minas Gerais, 30360680, Brazil\|Local Institution - 177, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil\|Local Institution - 182, Itajaí, Santa Catarina, 88301-220, Brazil\|Local Institution - 181, Salvador, 41950-610, Brazil\|Local Institution - 175, S?o Paulo, 01509-900, Brazil\|Local Institution - 527, Zagreb, Grad Zagreb, 10000, Croatia\|Local Institution - 525, Pula, 52100, Croatia\|Hopital Haut-Leveque - Maladies respiratoires, Pessac, Gironde, 33604, France\|Local Institution - 553, Saint-Herblain Cedex, Loire-Atlantique, 44800, France\|Centre Hospitalier Universitaire D' Angers H?pital Larrey - PNEUMOLOGIE, Angers, Maine-et-Loire, 49933, France\|Centre Hospitalier Universitaire de Poitiers, Poitiers, Poitou-Charentes, 86000, France\|Local Institution - 559, Grenoble, Rh?ne-Alpes, 0, France\|Local Institution - 560, Villefranche Sur Saone, Rh?ne, 69655, France\|Centre H?spitalier de Bretagne Sud - H?pital du Scorff, Lorient, 56322, France\|APHM Hopital Nord, Marseille, 13915, France\|CHU de Nantes - H?pital Nord La?nnec (HGRL), Nantes cedex 1, 44093, France\|Local Institution - 558, Quimper, 29000, France\|H?pital Bégin - Service d'Oncologie, Saint-Mandé, 94163, France\|Local Institution - 577, Patras, Acha?a, 265 04, Greece\|Local Institution - 575, Athens, Attiki, 11528, Greece\|Local Institution - 582, Athens, Attiki, 11528, Greece\|Local Institution - 579, Haidari - Athens, Attiki, 12462, Greece\|Local Institution - 576, Thessaloniki, Kentriki Makedonia, 54639, Greece\|Local Institution - 580, Panorama, 552 36, Greece\|Local Institution - 581, Thessaloniki, 56429, Greece\|Local Institution - 628, Tel Aviv-Yafo, Tel-Aviv, 64239, Israel\|Local Institution - 625, Jerusalem, Yerushalayim, 9103102, Israel\|Local Institution - 629, Haifa, 31048, Israel\|Local Institution - 627, Haifa, 3109601, Israel\|Local Institution - 626, Tel-Aviv, 6423906, Israel\|Local Institution - 778, Pesaro, Pesaro E Urbino, 61122, Italy\|Local Institution - 780, Candiolo, Torino, 10060, Italy\|Local Institution - 779, Milano, 20141, Italy\|Local Institution - 777, Novara, 28100, Italy\|Local Institution - 775, Perugia, 6132, Italy\|Local Institution - 776, Roma, 144, Italy\|National Cancer Center, Gyeonggido [Kyonggi-do], Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 10408, Korea, Republic of\|Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 6351, Korea, Republic of\|Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 8308, Korea, Republic of\|Gangnam Severance Hospital, Yonsei University Health System, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 6273, Korea, Republic of\|Local Institution - 128, Tuxtla Gutiérrez, Chiapas, 29038, Mexico\|Local Institution - 129, Cdmx, Distrito Federal, 3810, Mexico\|Local Institution - 127, Col. Roma, Distrito Federal, 0, Mexico\|Local Institution - 125, Toluca, 50090, Mexico\|Local Institution - 802, Breda, Noord-Brabant, 4818 CK, Netherlands\|Local Institution - 800, Amsterdam, Noord-Holland, 1066 CX, Netherlands\|Local Institution - 801, Nieuwegein, Utrecht, 3435 CM, Netherlands\|Local Institution - 650, Krakow, Malopolskie, 30-727, Poland\|Local Institution - 651, Gdynia, Pomorskie, 81-519, Poland\|Local Institution - 653, Lublin, 20-064, Poland\|Local Institution - 732, Cluj-Napoca, Cluj, 400641, Romania\|Local Institution - 731, Ovidiu, Constanta, 905900, Romania\|Local Institution - 729, Craiova, Dolj, 200385, Romania\|Local Institution - 734, Craiova, Dolj, 200542, Romania\|Local Institution - 730, Timisoara, Timis, 300166, Romania\|Local Institution - 733, Iasi, 700106, Romania\|Local Institution - 725, Sibiu, 550245, Romania\|Local Institution - 728, Suceava, 720214, Romania\|Local Institution - 753, Belgrade, Beograd, 11000, Serbia\|Local Institution - 754, Nis, Niaavski Okrug, 18000, Serbia\|Local Institution - 752, Kragujevac, ?umadijski Okrug, 34000, Serbia\|Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, A Coru?a, 15706, Spain\|Local Institution - 678, Malaga, Andalucía, 29010, Spain\|Local Institution - 676, Oviedo, Asturias, 33011, Spain\|Local Institution - 685, Palma de Mallorca, Baleares, 7120, Spain\|Local Institution - 684, Valencia, Valenciana, Comunidad, 46026, Spain\|Local Institution - 687, Barcelona, 8028, Spain\|Local Institution - 681, Barcelona, 8035, Spain\|Local Institution - 683, Barcelona, 8041, Spain\|Local Institution - 675, Madrid, 28007, Spain\|Local Institution - 679, Madrid, 28033, Spain\|Hospital Universitario Virgen De La Macarena, Sevilla, 41009, Spain\|Local Institution - 677, Valencia, 46010, Spain\|Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsuing City, Kaohsiung, 83301, Taiwan\|China Medical University Hospital - Internal Medicine, Taichung City, Taichung Municipality, 40447, Taiwan\|Chung Shan Medical University Hospital, Taichung City, Taichung, 40201, Taiwan\|Local Institution - 355, Taichung City, Taichung, 40705, Taiwan\|Local Institution - 377, Bangkok, Krung Thep Maha Nakhon [Bangkok], 10700, Thailand\|Local Institution - 376, Chiang Mai, 50200, Thailand\|Local Institution - 375, Khon Kaen, 40002, Thailand\|Local Institution - 378, Songkhla, 90110, Thailand\|Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi, Ankara, 6010, Turkey\|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, 6200, Turkey\|Memorial Ankara Hastanesi Tibbi Onkoloji, Ankara, 6520, Turkey\|Ankara Liv Hospital Tibbi Onkoloji, Ankara, 6680, Turkey\|Ankara Bilkent Sehir Hastanesi Tibbi Onkoloji Klinigi, Ankara, 6800, Turkey\|Trakya Univ Hastanesi Ic Hastal, Edirne, 22030, Turkey\|Local Institution - 709, Istanbul, 34214, Turkey\|Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey\|Istanbul Onkoloji Hastanesi Tibbi Onkoloji, Istanbul, 34846, Turkey\|Local Institution - 708, Izmir, 35100, Turkey Less <<
NCT05263986	Advanced or Metastatic Solid T... More >>umor Less <<	PHASE1	UNKNOWN	2023-10-31	Beijing Cancer Hospital, Beiji... More >>ng, Beijing, China\|Chongqing University Cancer Hospital, Chongqing, Chongqing, China\|Henan Cancer Hospital, Zhengzhou, Henan, China\|Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China\|Hunan Cancer Hospital, Changsha, Hunan, China\|The first Hospital of Jilin University, Changchun, Jilin, China\|Lin Yi Cancer Hospital, Linyi, Shandong, China\|Shanghai Chest Hospital, Shanghai, Shanghai, China Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.66mL 0.33mL 0.17mL	8.28mL 1.66mL 0.83mL	16.55mL 3.31mL 1.66mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed